WallStSmart

Aurora Cannabis Inc (ACB)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 750% more annual revenue ($3.17B vs $373.12M). UTHR leads profitability with a 40.6% profit margin vs -22.5%. UTHR earns a higher WallStSmart Score of 57/100 (C).

ACB

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -7.92

UTHR

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 5.3Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

UTHRUndervalued (+11.2%)

Margin of Safety

+11.2%

Fair Value

$535.96

Current Price

$564.94

$28.98 discount

UndervaluedFair: $535.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

UTHR4 strengths · Avg: 9.8/10
Profit MarginProfitability
40.6%10/10

Keeps 41 of every $100 in revenue as profit

Operating MarginProfitability
41.7%10/10

Strong operational efficiency at 41.7%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.3%9/10

Every $100 of equity generates 20 in profit

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$202.80M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

EPS GrowthGrowth
-94.7%2/10

Earnings declined 94.7%

UTHR3 concerns · Avg: 2.7/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.6%2/10

Revenue declined 1.6%

EPS GrowthGrowth
-12.2%2/10

Earnings declined 12.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Operating Margin, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ACB profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.

ACB carries more volatility with a beta of 1.33 — expect wider price swings.

ACB is growing revenue faster at 6.8% — sustainability is the question.

UTHR generates stronger free cash flow (363M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (57/100 vs 34/100), backed by strong 40.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?